Using Pharmacogenetics To Personalize Treatment Outcome To Ranibizumab (Lucentis) For The Eye Disease Age-related Macular Degeneration (AMD)
Funder
National Health and Medical Research Council
Funding Amount
$623,891.00
Summary
The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.